FDA accepts Merck's sublingual allergy med license application

Merck ($MRK) won the FDA's acceptance of a Biologics License Application for its investigational ragweed pollen allergy tablet to be delivered under the tongue. Working with ALK-Abello, Merck designed its tablet to treat allergic rhinitis--an inflammation of the nasal airways--by introducing small amounts of the allergen to initiate an immune response. The company expects the agency's review of this and another BLA for its Timothy-grass pollen sublingual tablet, accepted in March, to both be completed by the first half of 2014. Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…